Kiora Days Sales Outstanding from 2010 to 2025

KPRX Stock  USD 3.91  0.41  11.71%   
Kiora Pharmaceuticals Days Sales Outstanding yearly trend continues to be fairly stable with very little volatility. Days Sales Outstanding is likely to outpace its year average in 2025. During the period from 2010 to 2025, Kiora Pharmaceuticals Days Sales Outstanding regression line of annual values had r-squared of  0.69 and arithmetic mean of  1,020. View All Fundamentals
 
Days Sales Outstanding  
First Reported
2010-12-31
Previous Quarter
2.5 K
Current Value
2.6 K
Quarterly Volatility
1.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Kiora Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiora Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.2 K, Selling General Administrative of 4.8 M or Other Operating Expenses of 10.3 M, as well as many indicators such as Price To Sales Ratio of 16 K, Dividend Yield of 0.0 or PTB Ratio of 0.39. Kiora financial statements analysis is a perfect complement when working with Kiora Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Kiora Pharmaceuticals Correlation against competitors.
For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

Latest Kiora Pharmaceuticals' Days Sales Outstanding Growth Pattern

Below is the plot of the Days Sales Outstanding of Kiora Pharmaceuticals over the last few years. It is Kiora Pharmaceuticals' Days Sales Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiora Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Days Sales Outstanding10 Years Trend
Slightly volatile
   Days Sales Outstanding   
       Timeline  

Kiora Days Sales Outstanding Regression Statistics

Arithmetic Mean1,020
Geometric Mean109.01
Coefficient Of Variation130.48
Mean Deviation1,247
Median29.36
Standard Deviation1,331
Sample Variance1.8M
Range2.8K
R-Value0.83
Mean Square Error596,409
R-Squared0.69
Significance0.000074
Slope231.62
Total Sum of Squares26.6M

Kiora Days Sales Outstanding History

2025 2602.17
2024 2478.26
2020 2753.62
2019 0.66
2018 4.07
2017 21.21

About Kiora Pharmaceuticals Financial Statements

Kiora Pharmaceuticals investors use historical fundamental indicators, such as Kiora Pharmaceuticals' Days Sales Outstanding, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kiora Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Sales Outstanding2.5 K2.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.